Abstract
The role of 1,25-dihydroxyvitamin D 3 (1,25-(OH)2 D 3 ) as a regulator of cell growth and differentiation is well recognized. Currently, 1,25-(OH)2 D 3 and vitamin D analogs are being evaluated for their therapeutic potential in the treatment of hyperproliferative disorders like cancer. In the present review, we will discuss several processes that might be involved in 1,25-(OH)2 D 3 - and vitamin D analog-mediated suppression of cancer cell growth. The effects on tumor cell proliferation, differentiation, apoptosis, angiogenesis, metastases, and parathyroid hormone-related peptide secretion will be highlighted. In addition, combination therapy with other tumor effective drugs will be addressed. Furtermore, we will focus on the potential drawbacks and the possible side effects of vitamin D compounds in the treatment of cancer.
Keywords: Anti Tumor, 1 25 Dihydroxyvitamin D3, Vitamin D Analogs, Cancer, Breast Carcinoma, Myeloid leukemia, Cervical Carcinoma, Osteosarcoma, Colon carcinoma, Ovarian carcinoma, Colorectal carcinoma/kwd, >, Pancreatic carcinoma, Fibrosarcoma, Pituitary Adenoma, Gall Bladder carcinoma, Prostate carcinoma, Intestine carcinoma, Renal cell carcinoma, Lung carcinoma, Squamous cell carcinoma, Lymphocytic leukemia, Transitional bladder carcinoma, Melanoma, Thyroid carcinoma, Medullary thyroid carcinoma, Uterine carcinosarcoma, Reduced angiogenesis, Tumor suppression, Reduction of metastases, Cell proliferation, Apoptosis, Cell differentiation, Angiogenesis, Parathyroid hormone related peptide PTH rP, Metasaes, Growth factor, Osteosarcoma human, Prostate human, Melanoma human, erythroleukemia cell line K 562, Parathyroid Hormone Related Peptide Secretion, Metastasis, cadherins fibronectin VCAM 1, Vitamin D Resistance, 22 Oxo 1 25 dihydroxyvitamin D3, Transforming growth factor
Current Pharmaceutical Design
Title: Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Volume: 6 Issue: 7
Author(s): Gert-Jan C.M. van den Bemd, Huibert A.P. Pols and Johannes P.T.M. van Leeuwen
Affiliation:
Keywords: Anti Tumor, 1 25 Dihydroxyvitamin D3, Vitamin D Analogs, Cancer, Breast Carcinoma, Myeloid leukemia, Cervical Carcinoma, Osteosarcoma, Colon carcinoma, Ovarian carcinoma, Colorectal carcinoma/kwd, >, Pancreatic carcinoma, Fibrosarcoma, Pituitary Adenoma, Gall Bladder carcinoma, Prostate carcinoma, Intestine carcinoma, Renal cell carcinoma, Lung carcinoma, Squamous cell carcinoma, Lymphocytic leukemia, Transitional bladder carcinoma, Melanoma, Thyroid carcinoma, Medullary thyroid carcinoma, Uterine carcinosarcoma, Reduced angiogenesis, Tumor suppression, Reduction of metastases, Cell proliferation, Apoptosis, Cell differentiation, Angiogenesis, Parathyroid hormone related peptide PTH rP, Metasaes, Growth factor, Osteosarcoma human, Prostate human, Melanoma human, erythroleukemia cell line K 562, Parathyroid Hormone Related Peptide Secretion, Metastasis, cadherins fibronectin VCAM 1, Vitamin D Resistance, 22 Oxo 1 25 dihydroxyvitamin D3, Transforming growth factor
Abstract: The role of 1,25-dihydroxyvitamin D 3 (1,25-(OH)2 D 3 ) as a regulator of cell growth and differentiation is well recognized. Currently, 1,25-(OH)2 D 3 and vitamin D analogs are being evaluated for their therapeutic potential in the treatment of hyperproliferative disorders like cancer. In the present review, we will discuss several processes that might be involved in 1,25-(OH)2 D 3 - and vitamin D analog-mediated suppression of cancer cell growth. The effects on tumor cell proliferation, differentiation, apoptosis, angiogenesis, metastases, and parathyroid hormone-related peptide secretion will be highlighted. In addition, combination therapy with other tumor effective drugs will be addressed. Furtermore, we will focus on the potential drawbacks and the possible side effects of vitamin D compounds in the treatment of cancer.
Export Options
About this article
Cite this article as:
van den Bemd C.M. Gert-Jan, Pols A.P. Huibert and van Leeuwen P.T.M. Johannes, Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs, Current Pharmaceutical Design 2000; 6 (7) . https://dx.doi.org/10.2174/1381612003400498
DOI https://dx.doi.org/10.2174/1381612003400498 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets Identifying and Validating Oncology Therapeutic Targets in the Post- Genomics Era
Current Genomics Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Helicase Domain Containing Proteins in Human Disorders
Current Genomics Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Control of the Bone Morphogenetic Protein 7 Gene in Developmental and Adult Life
Current Genomics Using a Hybrid Radioenhancer to Discover Tumor Cell-targeted Treatment for Osteosarcoma: An In Vitro Study
Current Medicinal Chemistry Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design β-Aryl-ς-Hydroxy-γ-Lactones: Synthesis, Structural Analysis and Cytotoxic Activity
Current Organic Synthesis Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Inhibitor Binding to Hsp90: A Review of Thermodynamic, Kinetic, Enzymatic, and Cellular Assays
Current Protein & Peptide Science Regulating miRNAs Expression by Resveratrol: Novel Insights based on Molecular Mechanism and Strategies for Cancer Therapy
Current Molecular Pharmacology ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets